Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.
2.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
3.
4.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
5.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort.

J Antimicrob Chemother. 2007 Jun;59(6):1141-7. Epub 2007 Apr 13.

PMID:
17434879
6.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.

PMID:
17599319
7.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
8.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
9.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
11.

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.

García F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gomez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miró JM, Gatell JM; Spanish SCAN Study Group.

AIDS. 2000 Nov 10;14(16):2485-94.

PMID:
11101059
12.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
13.

HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.

Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.

Antivir Ther. 2007;12(6):971-5.

PMID:
17926652
14.

Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):429-34.

PMID:
11981357
15.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
16.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
17.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
18.

[Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].

Rey D, Schmitt MP, Hess-Kempf G, Krantz V, Partisani M, Bernard-Henry C, Lang JM.

Pathol Biol (Paris). 2001 Sep;49(7):559-66. French.

PMID:
11642019
19.

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.

Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barceló JJ, Vidal C, Cruceta A, Miró JM, Gatell JM.

AIDS. 2000 Sep 8;14(13):1921-33.

PMID:
10997396
20.

Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.

Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD.

J Infect Dis. 2000 Feb;181(2):522-31.

PMID:
10669335

Supplemental Content

Support Center